CoChat

Low-Dose Levothyroxine Reduces Intrahepatic Lipid Content in Patients With Type 2 Diabetes Mellitus and NAFLD

Open access

The DOI matches its Crossref record; 38 of the 39 references it cites were found in a registry or an index.

Abstract

Context: Nonalcoholic fatty liver disease (NAFLD) is highly prevalent in patients with type 2 diabetes mellitus (T2DM) and associated with significant morbidity and mortality. Thyroid hormone (TH) increases β-oxidation of fatty acids and decreases intrahepatic lipid content (IHLC) in rodents with NAFLD. Objective: We investigated the possibility of low intrahepatic TH concentration in NAFLD and studied the effect of TH treatment in humans. Design/Setting: This was a phase 2b single-arm study in six hospitals in Singapore. Intrahepatic thyroid hormone concentrations were measured in rats with induced NAFLD. Patients: Euthyroid patients with T2DM and steatosis measured by ultrasonography. Intervention: Levothyroxine was titrated to reach a thyroid-stimulating hormone level of 0.34 to 1.70 mIU/L before a 16-week maintenance phase. Main Outcome Measures: The primary outcome measure was change in IHLC measured by proton magnetic resonance spectroscopy after treatment. Results: Twenty male patients were included in the per-protocol analysis [mean ± SD: age, 47.8 ± 7.8 years; body mass index (BMI), 30.9 ± 4.4 kg/m2; baseline IHLC, 13% ± 4%]. After treatment, IHLC was decreased 12% (±SEM, 26%) relative to baseline (absolute change, -2%; 95% CI, -3 to 0; P = 0.046). Small decreases in BMI (P = 0.044), visceral adipose tissue volume (P = 0.047), and subcutaneous adipose tissue volume (P = 0.045) were observed. No significant changes in glucose regulation or lipid profile occurred. Conclusion: This study demonstrated the efficacy and safety of low-dose TH therapy for NAFLD in men. TH or TH analogs may be beneficial for this condition.

Overview

Integrity signals

Registry

Crossref · 10.1210/jc.2018-00475

Cites

38 of 38 references verified0 citation errors · 0 not checkable

Statistics

Recomputing p-values needs the paper’s full text.

Verification

Claims the paper makes

We couldn’t retrieve this paper’s full text, so its claims and self-check weren’t run. The registry and citation checks still apply.

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Citations

Cites

Show all 38 references

Cited by

See all 116

Metadata

Authors
Bruinstroop, E., Dalan, R., Cao, Y., Bee, Y. M., Chandran, K., Cho, L. W., Soh, S. B., Teo, E. K., Toh, S.-A., Leow, M. K. S., Sinha, R. A., Sadananthan, S. A., Michael, N., Stapleton, H. M., Leung, C., Angus, P. W., Patel, S. K., Burrell, L. M., Lim, S. C., Sum, C. F., Velan, S. S., & Yen, P. M.
Affiliations
  • Duke-NUS Medical School (SG)
  • Nanyang Technological University (SG)
  • Singapore Clinical Research Institute (SG)
  • Singapore General Hospital (SG)
  • Ng Teng Fong General Hospital (SG)
  • Changi General Hospital (SG)
  • National University Health System (SG)
  • Agency for Science, Technology and Research (SG)
  • Duke University (US)
  • The University of Melbourne (AU)
  • Khoo Teck Puat Hospital (SG)
Corresponding author
Yen, Paul M
Venue
The Journal of Clinical Endocrinology & Metabolism
Published
2018-04-27
Volume
103
Issue
7
Pages
2698-2706
ISSN
  • 0021-972X (ISSN-L)
  • 1945-7197
OpenAlex
W2802921027
Cited by
108
References
39
Citations by year
2026: 7 · 2025: 14 · 2024: 18 · 2023: 18 · 2022: 12 · 2021: 16 · 2020: 11 · 2019: 10 · 2018: 2
FWCI
7.61
Type
journal article
Language
en
Open access
Locations
  • The Journal of Clinical Endocrinology & Metabolism (publishedVersion)
  • PubMed (publishedVersion)
  • Pure Amsterdam UMC (publishedVersion, cc-by)
  • National University of Singapore (submittedVersion)
Funders
  • Duke-NUS Medical School
  • Koninklijke Nederlandse Akademie van Wetenschappen
  • Medical Research Council
  • National Health and Medical Research Council (629025, 1029990)
  • National Medical Research Council
Topics
  • Health Sciences › Medicine › Hepatology › Liver Disease Diagnosis and Treatment
  • Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Thyroid Disorders and Treatments
  • Health Sciences › Medicine › Pathology and Forensic Medicine › Alcohol Consumption and Health Effects
Keywords
levothyroxine, non-alcoholic fatty liver disease, type 2 diabetes, thyroid hormone replacement, hepatic steatosis, thyroid-stimulating hormone, fatty acid beta-oxidation, visceral adipose tissue, subcutaneous adipose tissue, 1H NMR
MeSH terms
Adult, Diabetes Mellitus, Type 2, Humans, Lipids, Liver, Male, Middle Aged, Thyroxine, Treatment Outcome, Young Adult, Non-alcoholic Fatty Liver Disease

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Low-Dose Levothyroxine Reduces Intrahepatic Lipid Content in Patients With Type 2 Diabetes Mellitus and NAFLD. https://app.cochat.ai/papers/10.1210/jc.2018-00475
The paper
Bruinstroop, E., Dalan, R., Cao, Y., Bee, Y. M., Chandran, K., Cho, L. W., Soh, S. B., Teo, E. K., Toh, S.-A., Leow, M. K. S., Sinha, R. A., Sadananthan, S. A., Michael, N., Stapleton, H. M., Leung, C., Angus, P. W., Patel, S. K., Burrell, L. M., Lim, S. C., . . . Yen, P. M. (2018). Low-Dose Levothyroxine Reduces Intrahepatic Lipid Content in Patients With Type 2 Diabetes Mellitus and NAFLD. The Journal of Clinical Endocrinology & Metabolism. https://doi.org/10.1210/jc.2018-00475

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.